PapersFlow Research Brief
Retinopathy of Prematurity Studies
Research Guide
What is Retinopathy of Prematurity Studies?
Retinopathy of Prematurity Studies encompass research on the diagnosis, treatment, and risk factors of retinopathy of prematurity, a potentially blinding eye disorder primarily affecting premature infants.
This field includes 23,538 works focused on screening examinations, intravitreal bevacizumab use, neurodevelopmental outcomes, and roles of vascular endothelial growth factor and oxygen in pathogenesis. "The International Classification of Retinopathy of Prematurity Revisited" by Classification of Retinopathy of Prematurity (2005) updated the 1984 consensus for standardizing disease staging with 2880 citations. "Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity" by Mintz-Hittner et al. (2011) compared bevacizumab to laser therapy, showing benefits in zone I disease with 1412 citations.
Topic Hierarchy
Research Sub-Topics
Intravitreal Bevacizumab for Retinopathy of Prematurity
Clinical trials and meta-analyses evaluate the efficacy, recurrence rates, and long-term retinal outcomes of anti-VEGF injections compared to laser therapy. Studies address dosing protocols and systemic safety in preterm infants.
Retinopathy of Prematurity Screening Protocols
Research develops standardized screening guidelines based on gestational age, birth weight, and telemedicine integration to optimize timing and reduce unnecessary exams. Validation studies assess sensitivity and cost-effectiveness across NICUs.
VEGF Pathogenesis in Retinopathy of Prematurity
Molecular studies elucidate the biphasic role of vascular endothelial growth factor in hyperoxia-induced vaso-obliteration and subsequent neovascularization phases. Animal models and human vitreous analyses identify therapeutic targets.
Neurodevelopmental Outcomes After Retinopathy of Prematurity
Longitudinal cohort studies track cognitive, motor, and visual development in ROP survivors, examining treatment effects and confounding prematurity risks. Neuroimaging correlates brain structure with functional outcomes.
Oxygen Therapy and Retinopathy of Prematurity Risk
Randomized trials optimize oxygen saturation targets to minimize ROP incidence without increasing mortality, incorporating pulse oximetry and genetic risk factors. Historical analyses contextualize current low-oxygen strategies.
Why It Matters
Retinopathy of prematurity studies guide screening and treatment to prevent blindness in premature infants. "Screening Examination of Premature Infants for Retinopathy of Prematurity" by Fierson et al. (2018) revised guidelines for preterm infants, addressing progression to tractional retinal detachment with 1392 citations. "Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity" by Mintz-Hittner et al. (2011) demonstrated intravitreal bevacizumab monotherapy superior to laser in zone I stage 3+ cases, allowing continued peripheral vessel development. "Revised Indications for the Treatment of Retinopathy of Prematurity" (2003) modified recommendations for peripheral retinal ablation in high-risk prethreshold ROP, reducing unfavorable outcomes.
Reading Guide
Where to Start
"The International Classification of Retinopathy of Prematurity Revisited" by Classification of Retinopathy of Prematurity (2005) provides the foundational staging system essential for understanding all subsequent studies.
Key Papers Explained
"The International Classification of Retinopathy of Prematurity Revisited" (2005) established standardized terminology, enabling "Revised Indications for the Treatment of Retinopathy of Prematurity" (2003) to define high-risk prethreshold criteria for early peripheral ablation. "Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity" by Mintz-Hittner et al. (2011) tested anti-vascular endothelial growth factor therapy building on pathogenesis insights from "Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity" by Alon et al. (1995). "Screening Examination of Premature Infants for Retinopathy of Prematurity" by Fierson et al. (2018) updated protocols using these classifications.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Studies continue evaluating long-term outcomes from early treatments like those in "Revised Indications for the Treatment of Retinopathy of Prematurity" (2003). Research applies classification from "The International Classification of Retinopathy of Prematurity Revisited" (2005) to refine zone-specific interventions. No recent preprints available.
Papers at a Glance
Frequently Asked Questions
What is the International Classification of Retinopathy of Prematurity?
The International Classification of Retinopathy of Prematurity (ICROP) was published in 1984 and expanded in 1987 as a consensus by experts. "The International Classification of Retinopathy of Prematurity Revisited" (2005) updated it to facilitate research and clinical management. It standardizes staging of retinal changes in premature infants.
How effective is intravitreal bevacizumab for retinopathy of prematurity?
Intravitreal bevacizumab monotherapy showed significant benefit over laser therapy for zone I stage 3+ retinopathy of prematurity. Peripheral retinal vessel development continued post-treatment. "Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity" by Mintz-Hittner et al. (2011) reported these findings in infants.
What are the screening guidelines for retinopathy of prematurity?
Screening targets preterm infants to detect retinopathy of prematurity before tractional retinal detachment. "Screening Examination of Premature Infants for Retinopathy of Prematurity" by Fierson et al. (2018) revised 2013 guidelines for immature retinal tissue. It specifies examination timing and criteria.
What role does vascular endothelial growth factor play in retinopathy of prematurity?
Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels. "Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity" by Alon et al. (1995) detailed this mechanism. It links to pathogenesis in premature infants.
What is the oxygen-induced retinopathy mouse model?
The oxygen-induced retinopathy mouse model reproduces retinal neovascularization for studying retinopathy of prematurity. "Oxygen-induced retinopathy in the mouse" by Smith et al. (1994) described this quantifiable model. It aids research on pathogenesis and interventions.
Open Research Questions
- ? How does oxygen exposure timing influence retinopathy of prematurity progression beyond mouse models?
- ? What are long-term neurodevelopmental outcomes after intravitreal bevacizumab versus laser treatment?
- ? Can classification systems predict treatment response in zone II retinopathy of prematurity?
- ? What genetic factors modulate vascular endothelial growth factor effects in human premature infants?
- ? How should screening intervals adapt to telemedicine advancements?
Recent Trends
The field comprises 23,538 works with no specified 5-year growth rate. "Screening Examination of Premature Infants for Retinopathy of Prematurity" by Fierson et al. represents recent guideline updates with 1392 citations.
2018No preprints or news from the last 12 months available.
Research Retinopathy of Prematurity Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Retinopathy of Prematurity Studies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers